NasdaqGM - Delayed Quote USD

iTeos Therapeutics, Inc. (ITOS)

10.56 +0.23 (+2.23%)
At close: 4:00 PM EDT
10.56 0.00 (0.00%)
After hours: 4:02 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Michel Detheux Ph.D. President, CEO & Director 922.38k -- 1967
Mr. Matthew A. Call M.B.A. Chief Operating Officer 638.55k -- 1973
Mr. Matthew Gall Chief Financial Officer 628.45k -- 1978
Dr. Yvonne McGrath Ph.D. Chief Scientific Officer -- -- 1974
Dr. Joyson Joseph Karakunnel FACP, M.D., M.Sc. Interim Chief Medical Officer -- -- 1971

iTeos Therapeutics, Inc.

321 Arsenal Street
Suite 301 Building 312
Watertown, MA 02472
United States
339 217 0161 https://www.iteostherapeutics.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
157

Description

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Corporate Governance

iTeos Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 8. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 8; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 08, 2024 - May 13, 2024
iTeos Therapeutics, Inc. Earnings Call

Related Tickers

BCAB BioAtla, Inc.
2.1050
-13.37%
 
ENTA Enanta Pharmaceuticals, Inc.
13.32
+0.68%
 
STRO Sutro Biopharma, Inc.
3.6300
-3.71%
 
RLAY Relay Therapeutics, Inc.
5.96
-2.45%
 
RPTX Repare Therapeutics Inc.
3.1500
+4.30%
 
DTIL Precision BioSciences, Inc.
9.74
-9.14%
 
INBX Inhibrx, Inc.
34.32
-0.38%
 
PCVX Vaxcyte, Inc.
60.83
+0.35%
 
SEER Seer, Inc.
1.6600
-5.14%
 
KYMR Kymera Therapeutics, Inc.
33.97
-3.27%